Sorafenib

製品コードS7397 別名：BAY 43-9006

分子量(MW)：464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

サイズ

価格(税別)

20mg	JPY 26400
50mg	JPY 46800
200mg	JPY 113200

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

具体的な在庫状況を確認してください。代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(134)

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

ターゲット

Raf-1 ^[1] (Cell-free assay)	mVEGFR2(Flk1) ^[1] (Cell-free assay)	mVEGFR3 ^[1] (Cell-free assay)	B-Raf ^[1] (Cell-free assay)	B-Raf (V599E) ^[1] (Cell-free assay)	もっとクリックする
6 nM	15 nM	20 nM	22 nM	38 nM	もっとクリックする

体外試験

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. ^[1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. ^[2]

細胞データ

Cell Lines	Assay Type	Activity Description	PMID
MV-4-11	NHzmNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\3TWM2OD1yLkCwNFAxOzB\|IN88US=>	Ml7OV2FPT0WU
MONO-MAC-6	NH2xd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLXdVlKSzVyPUCuNFA1OThizszN	NF\FTVlUSU6JRWK=
ALL-PO	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjiZ2dKSzVyPUCuNFMyQDRizszN	MmPpV2FPT0WU
NKM-1	NUj0[3dXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\xbmhIUUN3ME2wMlA4PDF4IN88US=>	NXXsOmZvW0GQR1XS
CGTH-W-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwMkWwNlIh\|ryP	MmH3V2FPT0WU
BB65-RCC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2D6RWlEPTB;MD60O\|A4OyEQvF2=	M{jjXnNCVkeHUh?=
NOS-1	NIH5dmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrkOYdKSzVyPUCuOVY{PiEQvF2=	M3XKW3NCVkeHUh?=
SH-4	NUPMfIJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLMdmVGUUN3ME2wMlY2PjF\|IN88US=>	NHXm[nVUSU6JRWK=
HOP-62	MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwOEWwPFgh\|ryP	NX7jZVhHW0GQR1XS
HCC2998	M1TCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknyTWM2OD1yLki4PFE5KM7:TR?=	NEHKRohUSU6JRWK=
GDM-1	M4DEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHez[ppKSzVyPUCuPVA3QThizszN	M33BR3NCVkeHUh?=
KM12	M3faeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlP0TWM2OD1zLkCyNFk5KM7:TR?=	MXvTRW5ITVJ?
LB2518-MEL	NIXhdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDQTWM2OD1zLkKwPFA6KM7:TR?=	MUTTRW5ITVJ?
NCI-H1436	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrxTWM2OD1zLkKxOlc5KM7:TR?=	NF\YRVlUSU6JRWK=
EM-2	Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmD4TWM2OD1zLkO1OVc5KM7:TR?=	MnfJV2FPT0WU
LAMA-84	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFwM{e2OFgh\|ryP	MUPTRW5ITVJ?
KG-1	M2f5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfoc4lKSzVyPUGuOFc6OzVizszN	M3T2ZXNCVkeHUh?=
A388	NGXTdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTCTWM2OD1zLkW5NVY2KM7:TR?=	M2PPNnNCVkeHUh?=
no-10	M1m3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTFwNkG3NlYh\|ryP	NUfYRXY6W0GQR1XS
SF126	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TrOGlEPTB;MT62N\|gyOiEQvF2=	M4XNTHNCVkeHUh?=
MEG-01	M{C4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvGUYlKSzVyPUGuPFA6QCEQvF2=	NVn1eGJqW0GQR1XS
A3-KAW	M2XRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHzenFKSzVyPUGuPFg1OiEQvF2=	M1HZPXNCVkeHUh?=
D-247MG	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3U[YtKSzVyPUKuNVQ1QCEQvF2=	MmPLV2FPT0WU
OVCAR-4	NIHLXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvuNmN5UUN3ME2yMlIyOzl\|IN88US=>	NIXMfZFUSU6JRWK=
NCI-SNU-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTJwM{G2NkDPxE1?	NWnqcJdPW0GQR1XS
NCI-H2171	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;0TnRKSzVyPUKuN\|k4PjRizszN	NXT1cplCW0GQR1XS
SIG-M5	NEnXZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjQT\|JFUUN3ME2yMlQzOjR{IN88US=>	MVzTRW5ITVJ?
BE-13	M{jXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnZ[oNbUUN3ME2yMlY6PjB7IN88US=>	M3L6[3NCVkeHUh?=
K052	NYTTcJh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mor0TWM2OD1{Lke0OlE3KM7:TR?=	NH\KSFdUSU6JRWK=
L-540	M2frOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnr2TWM2OD1{Lke1O\|g6KM7:TR?=	NHGw[ZdUSU6JRWK=
KMOE-2	M4\jfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDlZ5BKSzVyPUKuPFE{PSEQvF2=	NYLWXmN4W0GQR1XS
MFH-ino	MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHtVZpKSzVyPUKuPVIyQDVizszN	MVPTRW5ITVJ?
HL-60	NUfwR41lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTNwME[yPVkh\|ryP	M4\QV3NCVkeHUh?=
HCC2218	NWC4WZlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfid2pKSzVyPUOuNVIxODNizszN	MX;TRW5ITVJ?
TE-5	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTNwMUOxOlIh\|ryP	NX;SfndlW0GQR1XS
MZ1-PC	MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moj0TWM2OD1\|LkS3OVA6KM7:TR?=	NIWzO5VUSU6JRWK=
MRK-nu-1	NEPWcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37WdWlEPTB;Mz62NVQ3QCEQvF2=	MonPV2FPT0WU
MZ7-mel	M{npTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\ifHJKSzVyPUOuOlYxQTlizszN	MofYV2FPT0WU
BC-1	NVH0WlRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTNwN{SwNkDPxE1?	M2e0RnNCVkeHUh?=
ST486	M3mxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvubFdKSzVyPUOuPFM3PzNizszN	MnLwV2FPT0WU
KS-1	NGPwdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTNwOEixPVgh\|ryP	M1W4[nNCVkeHUh?=
SK-NEP-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXW[oZKSzVyPUSuNVY5OTVizszN	MXTTRW5ITVJ?
BC-3	M4HQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjpVGw2UUN3ME20MlI{OzlzIN88US=>	NXSzOZMzW0GQR1XS
NCI-H1581	M1S4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTRwMki3PVgh\|ryP	MlL5V2FPT0WU
MHH-PREB-1	NWX4XGh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHrTWM2OD12LkSwOFg1KM7:TR?=	NHz5d45USU6JRWK=
NOMO-1	MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[1ZXZCUUN3ME20MlQ5QTB3IN88US=>	Mk\1V2FPT0WU
QIMR-WIL	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLiTWM2OD13LkC3Nlk1KM7:TR?=	M2Sw[HNCVkeHUh?=
SF539	NHjSbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnYSoVPUUN3ME21MlE{OjJ5IN88US=>	NF\ucmZUSU6JRWK=
TE-12	M2\oNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LGNmlEPTB;NT6yOFkzQSEQvF2=	NUXXVI5yW0GQR1XS
NCI-H510A	MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzZUpJ3UUN3ME21MlQyPjh3IN88US=>	M33Je3NCVkeHUh?=
JAR	M4LVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPsRXl1UUN3ME21MlUxQDJ2IN88US=>	MlzZV2FPT0WU
no-11	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfySFBqUUN3ME21Mlc{PTZ6IN88US=>	MmfmV2FPT0WU
BV-173	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\tdWZzUUN3ME21Mlk2Pjh{IN88US=>	NH3YOYNUSU6JRWK=
SR	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnN[HRKSzVyPU[uNFA3PzhizszN	NXO4fIM3W0GQR1XS
MOLT-16	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPYTWM2OD14LkK1NlY3KM7:TR?=	NGKyOnZUSU6JRWK=
MZ2-MEL	NVP0fmJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17R[2lEPTB;Nj6zNVg{QSEQvF2=	M125S3NCVkeHUh?=
SW954	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXJVoVKSzVyPU[uOFU5PjZizszN	NVrUWVNrW0GQR1XS
ML-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYm4eI4{UUN3ME22MlUzQDR7IN88US=>	MYLTRW5ITVJ?
OCI-AML2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnKVlRKSzVyPU[uOlExPjJizszN	MVjTRW5ITVJ?
SIMA	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTdwMECxNFEh\|ryP	NYXl[INmW0GQR1XS
DOHH-2	NW\iZnJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTdwMEW2O\|Yh\|ryP	M1nwcnNCVkeHUh?=
697	MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2X6cWlEPTB;Nz6wOVk5QSEQvF2=	M3PEc3NCVkeHUh?=
NB1	NX3GemRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFz6bVVKSzVyPUeuOFA1ODdizszN	NXniOZpmW0GQR1XS
D-392MG	MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPqTWM2OD15Lk[yOlY{KM7:TR?=	NHy3T5VUSU6JRWK=
ES8	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFr0S5dKSzVyPUeuO\|Y2ODNizszN	NIXCdGdUSU6JRWK=
RPMI-8226	NWfZW\|hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnDUJhKSzVyPUeuPFQ2OTFizszN	NUTEcHVCW0GQR1XS
IST-MEL1	NV34WVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRThwNECwNFIh\|ryP	NVTvdYNbW0GQR1XS
NB14	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRThwNkOxN\|Mh\|ryP	MYDTRW5ITVJ?
HD-MY-Z	M{jVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPzbnFKSzVyPUiuOlM4PDZizszN	NFvtSVJUSU6JRWK=
TE-10	NYfLSmxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXmdXJXUUN3ME24Mlc3OzV\|IN88US=>	M4exTHNCVkeHUh?=
LC-1F	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEf6R4RKSzVyPUmuNVA5OzRizszN	NWW2WnlyW0GQR1XS
OS-RC-2	NF7YPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnwdVZkUUN3ME25MlEyOjR\|IN88US=>	MXjTRW5ITVJ?
NCI-SNU-16	MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTlwMkGwNlYh\|ryP	MmrDV2FPT0WU
SHP-77	NV31Zo8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\RTWM2OD17LkexOlYzKM7:TR?=	MornV2FPT0WU
A4-Fuk	MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjuTWM2OD17Lke1OlEh\|ryP	NIf0XndUSU6JRWK=
NB6	NXjWbVZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;h[mlEPTB;OT63OlAzQSEQvF2=	MVXTRW5ITVJ?
JiyoyeP-2003	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{m1WWlEPTB;MUCuOFc1PSEQvF2=	NFvwR3lUSU6JRWK=
DMS-114	NFLXc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH70W\|ZKSzVyPUGwMlU1PDFizszN	MmPIV2FPT0WU
NB7	NWPQcnlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLCSWJRUUN3ME2xNE44PTJ4IN88US=>	NWKwVmZjW0GQR1XS
NCI-H747	MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFzLkGyNVYh\|ryP	NELLO3NUSU6JRWK=
HH	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTFzLkO4O\|Yh\|ryP	NVrqWW1ZW0GQR1XS
EW-18	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFzLkmwOFQh\|ryP	M3z6OHNCVkeHUh?=
CHP-126	NHTjbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rBUmlEPTB;MUGuPVc{QCEQvF2=	M{DJcHNCVkeHUh?=
NTERA-S-cl-D1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTF{LkCyO\|gh\|ryP	M2r2[3NCVkeHUh?=
DEL	NUPxPZljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nvNGlEPTB;MUKuNFk5PSEQvF2=	M1vseXNCVkeHUh?=
LU-139	M3TRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIr0blRKSzVyPUGyMlU1OTNizszN	MnrxV2FPT0WU
P30-OHK	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTF{LkW0O\|kh\|ryP	NXPXbYJQW0GQR1XS
NCI-H1522	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2mxW2lEPTB;MUKuO\|Q3KM7:TR?=	Mo\4V2FPT0WU
NCI-H1299	MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTF\|LkK5NVEh\|ryP	MX;TRW5ITVJ?
UACC-257	Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjUTWM2OD1zMz61NVI3KM7:TR?=	Mlj4V2FPT0WU
Calu-6	NH3kdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2K5RmlEPTB;MUOuOlA1PiEQvF2=	NFz4ZpBUSU6JRWK=
NCI-H1882	M3;JPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDQUYpKSzVyPUGzMlg2PTVizszN	NV7vSXptW0GQR1XS
BB30-HNC	NWjYTm9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYeyN3NzUUN3ME2xOE4xPjB7IN88US=>	M4XNdXNCVkeHUh?=
ES1	NXyzZWlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTF2LkG1OVEh\|ryP	MV7TRW5ITVJ?
NCI-H1694	NITCPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUS5VIg1UUN3ME2xOE41QDFzIN88US=>	NWH5NWM5W0GQR1XS
IST-SL1	NVLvUmpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzyTWM2OD1zND65OlE3KM7:TR?=	NYjlemg5W0GQR1XS
ECC4	Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PuOWlEPTB;MUWuNFU2QCEQvF2=	MlrGV2FPT0WU
MDA-MB-134-VI	NUPzSVdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDFNXBtUUN3ME2xOU41OTNzIN88US=>	NETUUJhUSU6JRWK=
SCH	NUXSU\|BYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\ISmlEPTB;MUWuOFczQCEQvF2=	MlPjV2FPT0WU
SK-N-FI	M3TxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfYTWM2OD1zNT62OVM1KM7:TR?=	MmjxV2FPT0WU
HDLM-2	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrEdo1KSzVyPUG2MlA4OTRizszN	MoXRV2FPT0WU
Ramos-2G6-4C10	NHXSSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;3S4hKSzVyPUG2MlEzQTdizszN	M3nDfnNCVkeHUh?=
EW-24	M4HLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTF4LkG2OlEh\|ryP	MmjwV2FPT0WU
NCI-H2141	M1PKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:5TWM2OD1zNj6xPFkh\|ryP	NIXoVYpUSU6JRWK=
LC4-1	NVTOfHVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPtcZNKSzVyPUG2MlYyOTlizszN	NILQ[G1USU6JRWK=
HT-144	MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LkOWlEPTB;MUeuNFA3KM7:TR?=	NWfrZlA5W0GQR1XS
SK-MEL-1	M2PROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1e5VWlEPTB;MUeuNFA4OiEQvF2=	NEnsUFdUSU6JRWK=
SCC-15	Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHpTWM2OD1zNz6xOlM5KM7:TR?=	NF;tfJZUSU6JRWK=
C8166	M{na[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn6wTWM2OD1zNz62PFM{KM7:TR?=	NUPZbYM3W0GQR1XS
GOTO	NXXqN3VYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXu0XnR{UUN3ME2xO{45OzR2IN88US=>	M17ocXNCVkeHUh?=
COR-L279	NGTnW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTF6LkGzOlIh\|ryP	MUHTRW5ITVJ?
K-562	NYnzRYEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTF6LkexOFMh\|ryP	NVXpWIp3W0GQR1XS
ES3	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\2OXNKSzVyPUG4MlgxPDFizszN	MmHIV2FPT0WU
LU-165	M1LsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLQNZNJUUN3ME2xPU44ODB6IN88US=>	MkezV2FPT0WU
KM-H2	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1W2XGlEPTB;MkCuN\|E5PCEQvF2=	Mn[0V2FPT0WU
RL	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LoTWlEPTB;MkCuPVY6OiEQvF2=	NUfrRZhVW0GQR1XS
EW-3	Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTJzLkG4PFkh\|ryP	NHjW[GhUSU6JRWK=
A101D	M{\ue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XrfWlEPTB;MkGuN\|c2OiEQvF2=	NFfRUm9USU6JRWK=
HUTU-80	NWWyXnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXFblNrUUN3ME2yNU4{QTR4IN88US=>	NY\hepVoW0GQR1XS
NCI-H23	MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlX3TWM2OD1{MT6zPVkzKM7:TR?=	MnjHV2FPT0WU
PF-382	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moq5TWM2OD1{MT60OFA{KM7:TR?=	M2[xenNCVkeHUh?=
LB373-MEL-D	NGmzSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzWdYpIUUN3ME2yNU42PjF3IN88US=>	NWPqeWNYW0GQR1XS
TE-8	NFPWUI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1qzc2lEPTB;MkGuOlM6PCEQvF2=	MnrUV2FPT0WU
TE-9	NXLFeY5rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGK1UnhKSzVyPUKxMlg2OTNizszN	NE[2b3VUSU6JRWK=
Daudi	NIrYTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTJzLkmzNFQh\|ryP	MoO4V2FPT0WU
D-542MG	NHPTRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1X5d2lEPTB;MkKuNFI2PiEQvF2=	M4DTOXNCVkeHUh?=
U-698-M	NIDGWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fuNWlEPTB;MkKuOFYxOyEQvF2=	NYHFfWxmW0GQR1XS
ES6	MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkf4TWM2OD1{Mj63N\|Y3KM7:TR?=	Mlq0V2FPT0WU
DU-4475	MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\zdGlEPTB;MkOuPFg6PyEQvF2=	NX\FS2dsW0GQR1XS
ECC12	MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\mTWM2OD1{ND6yPFA{KM7:TR?=	MYrTRW5ITVJ?
C2BBe1	NIXKboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn64TWM2OD1{ND6zNlM6KM7:TR?=	M4HnR3NCVkeHUh?=
IST-SL2	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETIV4lKSzVyPUK0MlQ{PjJizszN	M{fYTnNCVkeHUh?=
DJM-1	NHryfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkL6TWM2OD1{ND61NlIyKM7:TR?=	MoSxV2FPT0WU
DMS-153	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXm4[nhkUUN3ME2yOE45PjF2IN88US=>	NHvXT2lUSU6JRWK=
NB13	MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDkPZZyUUN3ME2yOU4xOjZ3IN88US=>	MYLTRW5ITVJ?
SK-N-DZ	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;UTWM2OD1{Nj6zOFE1KM7:TR?=	MXvTRW5ITVJ?
COR-L88	M{PqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnv1TWM2OD1{Nj61O\|k3KM7:TR?=	NVPBfZhGW0GQR1XS
LU-65	NUXlUGUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrSbYRKSzVyPUK2Mlg2OzVizszN	MUXTRW5ITVJ?
TGBC1TKB	M3vJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;pTGlEPTB;Mk[uPVgzQCEQvF2=	M33GS3NCVkeHUh?=
THP-1	M37rVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTJ5LkKxOFEh\|ryP	MXzTRW5ITVJ?
ONS-76	NX7ybGVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LkNmlEPTB;MkeuN\|MzKM7:TR?=	MVLTRW5ITVJ?
LC-2-ad	M{OwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTJ5Lk[yN\|Eh\|ryP	M2S5R3NCVkeHUh?=
EW-13	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTJ7LkG3OFYh\|ryP	MWDTRW5ITVJ?
MS-1	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\uO2lEPTB;M{CuO\|I4QCEQvF2=	NGToOIZUSU6JRWK=
NCI-H2227	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\Gb4ZKSzVyPUOwMlk5ODZizszN	NUPzfGFoW0GQR1XS
LXF-289	NFXxO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWG1THNQUUN3ME2zNU41PDl{IN88US=>	MWPTRW5ITVJ?
MC116	NIjvSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3ZV4FKUUN3ME2zNk4xQDJ4IN88US=>	NHTLZWFUSU6JRWK=
EVSA-T	NFiy[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4P3S2lEPTB;M{KuNlU5PSEQvF2=	MXrTRW5ITVJ?
CTB-1	M3z1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPaT3R3UUN3ME2zN{4yOTBzIN88US=>	M{H0SXNCVkeHUh?=
COLO-320-HSR	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTN\|LkG2NFMh\|ryP	MX3TRW5ITVJ?
NCI-H2196	Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4G1N2lEPTB;M{OuNlU2PyEQvF2=	MVrTRW5ITVJ?
LB2241-RCC	Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTN\|LkOxN\|Uh\|ryP	NYTJc4hrW0GQR1XS
LS-513	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLlSVBnUUN3ME2zN{45PjN6IN88US=>	MX7TRW5ITVJ?
LP-1	NWHNbGxLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fKc2lEPTB;M{OuPVk2PiEQvF2=	MoPrV2FPT0WU
A253	NYj1XIRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2ftR2lEPTB;M{SuNlI6PiEQvF2=	MlTBV2FPT0WU
SK-MM-2	NUP3ZWkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXjdWVKSzVyPUO0Mlk1PTFizszN	MYjTRW5ITVJ?
NCI-H1963	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvkTWM2OD1\|NT6zNFczKM7:TR?=	NVHGT3doW0GQR1XS
MMAC-SF	M2DpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTN3Lki3PFUh\|ryP	NGnwfpRUSU6JRWK=
LB831-BLC	NXT1ZlVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVW1dFR4UUN3ME2zOk4xPjV2IN88US=>	NXfrd3VSW0GQR1XS
WSU-NHL	NEnoUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXz4cohYUUN3ME2zOk4yPjRizszN	NVzIO21{W0GQR1XS
CESS	MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTN4LkK4OFgh\|ryP	M4TDNXNCVkeHUh?=
NEC8	NXT6Slh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGqyVWFKSzVyPUO2MlU5OzVizszN	MYrTRW5ITVJ?
KNS-42	MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Ly[mlEPTB;M{euNVI{PyEQvF2=	MYrTRW5ITVJ?
MHH-CALL-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmWzTWM2OD1\|Nz6xPFIyKM7:TR?=	MVTTRW5ITVJ?
K5	NHzEbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvGXZhKSzVyPUO4MlQ{KM7:TR?=	MoHFV2FPT0WU
CP66-MEL	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWK5S5ExUUN3ME2zPU4xPzN\|IN88US=>	NV23TFJtW0GQR1XS
OPM-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTN7Lki0N\|Ih\|ryP	MkfFV2FPT0WU
IST-MES1	M4DrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTyTWM2OD12MD6zNFk3KM7:TR?=	NXjwV4psW0GQR1XS
EC-GI-10	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWG2OWFbUUN3ME20NU42QDB3IN88US=>	NGDqRnFUSU6JRWK=
CTV-1	Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTR{Lki0NFYh\|ryP	M4\vXXNCVkeHUh?=
DG-75	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPDTWM2OD12Mz63OVk2KM7:TR?=	NHXTXYpUSU6JRWK=
KNS-81-FD	M{jBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;BXIt1UUN3ME20OU41ODV6IN88US=>	M4jCRnNCVkeHUh?=
NCI-H82	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoL0TWM2OD12NT61O\|U5KM7:TR?=	NXzYT3VJW0GQR1XS
RPMI-8866	M4q5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTsbphRUUN3ME20Ok4yQDd\|IN88US=>	M4r5dHNCVkeHUh?=
ACN	NHfMOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\mR2lEPTB;NE[uOFM1KM7:TR?=	NFuyfnZUSU6JRWK=
NCI-H1395	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\l[lVKSzVyPUS2MlQ4PTZizszN	MV7TRW5ITVJ?
NCI-H209	M4TMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XTXmlEPTB;NEeuNVQxPSEQvF2=	MVPTRW5ITVJ?
TGW	M{j2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTR7LkC3PVEh\|ryP	MYrTRW5ITVJ?
NCI-H748	M3\lXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nzWWlEPTB;NEmuOFc2OyEQvF2=	NITwO4lUSU6JRWK=
EKVX	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vUR2lEPTB;NEmuOlYzQCEQvF2=	MV7TRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	LC3-I / LC-3II / ATG5; PubMed: 23392173 Cell Death Dis Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot. p-STAT3 / STAT3 / Mcl-1; PubMed: 23392173 Cell Death Dis Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. β-catenin / Survivin / Mcl-1 / PTMA; PubMed: 26517516 Oncotarget Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels. pERK / ERK; PubMed: 22286758 Oncogene Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib. p-PKM2(y105) / PMK2 / Caspase-9; PubMed: 26959741 Oncotarget Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h. RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); PubMed: 22941289 Acta Pharmacol Sin Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells. Cyclin D1; PubMed: 26039995 Proc Natl Acad Sci U S A Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.	23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay	Cell viability; PubMed: 26039995 Proc Natl Acad Sci U S A Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).	26039995
Immunofluorescence	p65; PubMed: 22286758 Oncogene HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown. cytochrome c; PubMed: 22278289 Cell Death Dis Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.	22286758 22278289
ELISA	TGF-beta / CD206; PubMed: 26158762 Oncotarget In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA. Caspase-9 / Caspase-3; PubMed: 30923462 Cancer Cell Int Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.	26158762 30923462

体内試験

Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. ^[1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. ^[2] Sorafenib sensitizes bax^-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax^-/- and HT29 tumor xenografts. ^[3]

お薦めの試験操作（参考用のみ）

キナーゼ試験： ^[1]	+ 展開 Biochemical assays: Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl₂, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[³³P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl₂, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
細胞試験： ^[1]	+ 展開細胞株： MDA-MB-231, and HAoSMC 濃度： Dissolved in DMSO, final concentrations ~10 μM 反応時間： 72 hours 実験の流れ： Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP. (参考用のみ)
動物試験： ^[1]	+ 展開動物モデル： Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells 製剤： Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water 投薬量： ~60 mg/kg 投与方法： Orally once daily (参考用のみ)

参考

溶解度 (25°C)

体外	DMSO	63 mg/mL (135.53 mM) warming
	Water	Insoluble
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5% DMSO+45% PEG 400+ddH2O 混合させたのち直ちに使用することを推奨します。	3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Sorafenib SDFをダウンロードする

分子量	464.82
化学式	C₂₁H₁₆ClF₃N₄O₃
CAS No.	284461-73-0
保管	3年 -20°C 粉
保管	2年 -80°C in solvent
別名	BAY 43-9006

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03780634	Not yet recruiting	Hepatocellular Carcinoma	Sun Yat-sen University\|Kaiping Central Hospital\|Guangzhou No.12 People''s Hospital	April 1 2019	Phase 2
NCT03780634	Not yet recruiting	Hepatocellular Carcinoma	Sun Yat-sen University\|Kaiping Central Hospital\|Guangzhou No.12 People''s Hospital	April 1 2019	Phase 2
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03644511	Recruiting	Hepatocellular Carcinoma	Bayer	February 28 2019	--
NCT03606590	Recruiting	Hepatocellular Carcinoma	NovoCure GmbH\|NovoCure Ltd.	February 15 2019	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

Rafシグナル伝達経路

相関Raf製品

LY3009120

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
GDC-0994

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523, VRT752271)

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032, RG7204)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Dabrafenib (GSK2118436)

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
Sorafenib Tosylate

Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

研究分野別

製品類型

Sorafenib

文献中Selleckの製品使用例(134)

製品安全説明書

Raf阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Sorafenib SDFをダウンロードする

便利ツール

モル濃度計算器

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技術サポート

Rafシグナル伝達経路

相関Raf製品